Abstract | OBJECTIVE: To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs). METHOD: MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB). RESULTS: The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index. CONCLUSIONS: Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.
|
Authors | Marilyn Huckans, Stephen Boyd, Grant Moncrief, Nathan Hantke, Bethany Winters, Kate Shirley, Emily Sano, Holly McCready, Laura Dennis, Milky Kohno, William Hoffman, Jennifer M Loftis |
Journal | Journal of clinical and experimental neuropsychology
(J Clin Exp Neuropsychol)
Vol. 43
Issue 6
Pg. 599-610
(08 2021)
ISSN: 1744-411X [Electronic] England |
PMID | 34612792
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Amphetamine-Related Disorders
(complications)
- Cognition
- Executive Function
- Humans
- Methamphetamine
(adverse effects)
- Neuropsychological Tests
|